How anti-BAFF and anti-IFNAR1 compare in this context is still uncertain but given the important role of type I IFN in antiviral immunity remains important gather more long-term data how anti-IFNAR1 therapy affects the risk for severe COVID-19 severe HZ and its consequences such as post-herpetic neuralgia or other viral infections. The gene discussed is TNFSF13B; the disease is COVID-19.